Robert F. Kennedy Jr appears poised to be among the most influential figures in Donald Trump’s second White House stint, but ...
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback